- Corporate Officers - S
- Scopa James Paul
Insider Trading History of Scopa James Paul
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Scopa James Paul since 2009.
This trader's CIK number is 1356950.
At the time of last reporting, Scopa James Paul was the Officer of Adverum Biotechnologies, Inc.. (stock ticker symbol ADVM).
Also see all insider trading activities at Adverum Biotechnologies, Inc..
Note that in the past
Scopa James Paul also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Histogen Inc. (CNAT) by Scopa James Paul
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2013 | CNAT | 165,265 | $1,817,915 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Adverum Biotechnologies, Inc. (ADVM) by Scopa James Paul
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | ADVM | 100,000 | $135,000 | 0 | $0 | 0 | $0 |
| 2021 | ADVM | 0 | $0 | 50,000 | $109,000 | 0 | $0 |
| 2020 | ADVM | 10,000 | $137,500 | 0 | $0 | 23,334 | $151,204 |
| 2019 | ADVM | 20,000 | $134,200 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Peplin Inc (PLI) by Scopa James Paul
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2009 | PLI | 33,910 | $266,232 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Dice Therapeutics, Inc. (DICE) by Scopa James Paul
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | DICE | 0 | $0 | 10,000 | $290,500 | 0 | $0 |
| 2021 | DICE | 6,000 | $102,000 | 0 | $0 | 0 | $0 |
Insider trading activities at 4 companies by Scopa James Paul:
1. Histogen Inc. (CNAT)
2. Adverum Biotechnologies, Inc. (ADVM)
3. Peplin Inc (PLI)
4. Dice Therapeutics, Inc. (DICE)
Table 1. Insider trading of Histogen Inc. (CNAT) by Scopa James Paul
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2013-07-30 | CNAT | Buy | 165,265 | 11.00 | 1,817,915 |
Table 2. Insider trading of Adverum Biotechnologies, Inc. (ADVM) by Scopa James Paul
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-02-07 | ADVM | Buy | 100,000 | 1.35 | 135,000 |
| 2021-11-15 | ADVM | Sale | 50,000 | 2.18 | 109,000 |
| 2020-05-04 | ADVM | Option Ex | 23,334 | 6.48 | 151,204 |
| 2020-02-14 | ADVM | Buy | 10,000 | 13.75 | 137,500 |
| 2019-05-06 | ADVM | Buy | 20,000 | 6.71 | 134,200 |
Table 3. Insider trading of Peplin Inc (PLI) by Scopa James Paul
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2009-02-11 | PLI | Buy | 999 | 8.00 | 7,992 |
| 2009-02-12 | PLI | Buy | 1,249 | 8.20 | 10,241 |
| 2009-02-09 | PLI | Buy | 999 | 8.00 | 7,992 |
| 2009-02-05 | PLI | Buy | 2,648 | 7.80 | 20,654 |
| 2009-01-23 | PLI | Buy | 6,029 | 8.00 | 48,232 |
| 2009-01-27 | PLI | Buy | 1,678 | 8.20 | 13,759 |
| 2009-01-21 | PLI | Buy | 932 | 8.00 | 7,456 |
| 2009-01-22 | PLI | Buy | 2,583 | 8.10 | 20,922 |
| 2009-01-20 | PLI | Buy | 45 | 8.40 | 378 |
| 2009-01-19 | PLI | Buy | 899 | 8.20 | 7,371 |
| 2009-01-16 | PLI | Buy | 7,340 | 8.20 | 60,187 |
| 2009-01-15 | PLI | Buy | 1,598 | 7.80 | 12,464 |
| 2009-01-13 | PLI | Buy | 6,911 | 7.03 | 48,584 |
Table 4. Insider trading of Dice Therapeutics, Inc. (DICE) by Scopa James Paul
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-03-17 | DICE | Sale | 10,000 | 29.05 | 290,500 |
| 2021-09-15 | DICE | Buy | 6,000 | 17.00 | 102,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Scopa James Paul
(Officer of Adverum Biotechnologies, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.